Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The PROGRESS Study: Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implants Following Surgical Opening of the Frontal Sinus for Chronic Sinusitis: A Randomized Blinded Controlled Study

Trial Profile

The PROGRESS Study: Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implants Following Surgical Opening of the Frontal Sinus for Chronic Sinusitis: A Randomized Blinded Controlled Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mometasone (Primary)
  • Indications Sinusitis
  • Focus Registrational; Therapeutic Use
  • Acronyms PROGRESS
  • Sponsors Intersect ENT
  • Most Recent Events

    • 20 May 2021 According to an Intersect ENT media release, based on the positive data from the PROPEL Contour cohort of this US clinical study, the company has received CE Mark approval for the companys PROPEL Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union.
    • 02 Nov 2017 Results for the second cohort published in an Intersect ENT media release.
    • 02 Nov 2017 According to an Intersect ENT media release, results for the second cohort were published in the Journal of the American Medical Association Otolaryngology Head and Neck Surgery.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top